EU/3/18/2133: Orphan designation for the treatment of soft tissue sarcoma

Vinorelbine tartrate


On 11 January 2019, orphan designation (EU/3/18/2133) was granted by the European Commission to TLC Biopharmaceuticals B.V., the Netherlands, for vinorelbine tartrate for the treatment of soft tissue sarcoma.

Key facts

Active substance
Vinorelbine tartrate
Intended use
Treatment of soft tissue sarcoma
Orphan designation status
EU designation number
Date of designation

J.h. Oortweg 19
2333 CH Leiden
Tel. + 31 (0) 71 33 22 340

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.


Documents related to this orphan designation evaluation

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

EU register of orphan medicines

The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

How useful was this page?

Add your rating